Researchers from the National Clinical Research Center for Metabolic Disease, Hunan, China, studied 16 random controlled clinical trials comprising 3729 subjects in the metanalyses and found that anti-inflammatory therapies targeting the pathogenic process of diabetes can significantly reduce the level of fasting plasma glucose (FPG), HbA1c, and CRP in patients with type-2 diabetes [115]. This evidence concerns the gene CRP and diabetes mellitus.